Bortezomib in the treatment of antibody‐mediated rejection in pediatric kidney transplant recipients: A multicenter Midwest Pediatric Nephrology Consortium study

Overview of attention for article published in Pediatric Transplantation, January 2017

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter: 5 X users

Readers on

mendeley: 38 Mendeley

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 34,155 followers.

RT @ASPNeph: Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney #transplant recipients: MWPNC study https://t.c…

RT @rheault_m: Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplantation #MWPNC @priyagoose https://t.…

Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplantation #MWPNC @priyagoose https://t.co/ZMoiaQGIeK

RT @ASPNeph: Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney #transplant recipients: MWPNC study https://t.c…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.